Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

PROCEPT BioRobotics (PRCT) EBITDA Margin (2020 - 2025)

PROCEPT BioRobotics (PRCT) has disclosed EBITDA Margin for 6 consecutive years, with 39.08% as the latest value for Q4 2025.

  • On a quarterly basis, EBITDA Margin fell 1164.0% to 39.08% in Q4 2025 year-over-year; TTM through Dec 2025 was 31.05%, a 966.0% increase, with the full-year FY2025 number at 31.05%, up 966.0% from a year prior.
  • EBITDA Margin was 39.08% for Q4 2025 at PROCEPT BioRobotics, down from 25.47% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 25.19% in Q2 2025 to a low of 181.13% in Q4 2021.
  • A 5-year average of 89.05% and a median of 73.29% in 2023 define the central range for EBITDA Margin.
  • Biggest YoY gain for EBITDA Margin was 35830bps in 2021; the steepest drop was -104499bps in 2021.
  • PROCEPT BioRobotics' EBITDA Margin stood at 181.13% in 2021, then skyrocketed by 34bps to 119.42% in 2022, then skyrocketed by 47bps to 62.9% in 2023, then surged by 56bps to 27.44% in 2024, then tumbled by -42bps to 39.08% in 2025.
  • Per Business Quant, the three most recent readings for PRCT's EBITDA Margin are 39.08% (Q4 2025), 25.47% (Q3 2025), and 25.19% (Q2 2025).